JP2022523533A - 嚥下可能なデバイスから患者の腸管の中への推進薬物送達 - Google Patents
嚥下可能なデバイスから患者の腸管の中への推進薬物送達 Download PDFInfo
- Publication number
- JP2022523533A JP2022523533A JP2021550224A JP2021550224A JP2022523533A JP 2022523533 A JP2022523533 A JP 2022523533A JP 2021550224 A JP2021550224 A JP 2021550224A JP 2021550224 A JP2021550224 A JP 2021550224A JP 2022523533 A JP2022523533 A JP 2022523533A
- Authority
- JP
- Japan
- Prior art keywords
- capsule
- wall
- therapeutic agent
- propellant
- swallowable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims description 23
- 238000012377 drug delivery Methods 0.000 title description 27
- 230000001141 propulsive effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 241
- 239000002775 capsule Substances 0.000 claims abstract description 217
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 105
- 239000003380 propellant Substances 0.000 claims abstract description 85
- 238000002360 preparation method Methods 0.000 claims abstract description 83
- 238000000034 method Methods 0.000 claims abstract description 63
- 210000002784 stomach Anatomy 0.000 claims abstract description 57
- 230000004044 response Effects 0.000 claims abstract description 24
- 230000002496 gastric effect Effects 0.000 claims description 114
- 230000008602 contraction Effects 0.000 claims description 35
- 230000000149 penetrating effect Effects 0.000 claims description 34
- 230000002572 peristaltic effect Effects 0.000 claims description 33
- 239000000020 Nitrocellulose Substances 0.000 claims description 22
- 239000003990 capacitor Substances 0.000 claims description 22
- 229920001220 nitrocellulos Polymers 0.000 claims description 22
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 210000000936 intestine Anatomy 0.000 claims description 15
- 239000012530 fluid Substances 0.000 claims description 12
- 238000002485 combustion reaction Methods 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 2
- 238000007599 discharging Methods 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 134
- 210000000813 small intestine Anatomy 0.000 abstract description 42
- 238000002347 injection Methods 0.000 abstract description 5
- 239000007924 injection Substances 0.000 abstract description 5
- 239000013256 coordination polymer Substances 0.000 abstract 2
- 238000010586 diagram Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 68
- 239000000463 material Substances 0.000 description 39
- 239000007787 solid Substances 0.000 description 35
- 230000035515 penetration Effects 0.000 description 33
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 32
- 230000000968 intestinal effect Effects 0.000 description 25
- 238000011282 treatment Methods 0.000 description 23
- 230000007246 mechanism Effects 0.000 description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 19
- 239000008103 glucose Substances 0.000 description 19
- 102000004877 Insulin Human genes 0.000 description 16
- 108090001061 Insulin Proteins 0.000 description 16
- 229940125396 insulin Drugs 0.000 description 16
- 210000001187 pylorus Anatomy 0.000 description 16
- 239000007788 liquid Substances 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 230000001079 digestive effect Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000001198 duodenum Anatomy 0.000 description 11
- 238000000465 moulding Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 9
- 108010011459 Exenatide Proteins 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 229960001519 exenatide Drugs 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 239000000122 growth hormone Substances 0.000 description 8
- 239000000859 incretin Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 108010051696 Growth Hormone Proteins 0.000 description 7
- 102000018997 Growth Hormone Human genes 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 239000007884 disintegrant Substances 0.000 description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 229920002988 biodegradable polymer Polymers 0.000 description 6
- 239000004621 biodegradable polymer Substances 0.000 description 6
- 208000028659 discharge Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000002429 large intestine Anatomy 0.000 description 6
- 230000008855 peristalsis Effects 0.000 description 6
- 229940124531 pharmaceutical excipient Drugs 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- -1 antibodies Proteins 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000008482 dysregulation Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 5
- 239000000199 parathyroid hormone Substances 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 230000001960 triggered effect Effects 0.000 description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 102000003982 Parathyroid hormone Human genes 0.000 description 4
- 108090000445 Parathyroid hormone Proteins 0.000 description 4
- 210000003484 anatomy Anatomy 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 150000004283 biguanides Chemical class 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- 229960001319 parathyroid hormone Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000000935 solvent evaporation Methods 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940123208 Biguanide Drugs 0.000 description 3
- 108010019598 Liraglutide Proteins 0.000 description 3
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 3
- 210000004913 chyme Anatomy 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229960002701 liraglutide Drugs 0.000 description 3
- 229920000193 polymethacrylate Polymers 0.000 description 3
- 239000002510 pyrogen Substances 0.000 description 3
- 238000000197 pyrolysis Methods 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 210000002370 ICC Anatomy 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000573 anti-seizure effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003430 antimalarial agent Substances 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 229940125687 antiparasitic agent Drugs 0.000 description 2
- 238000000418 atomic force spectrum Methods 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000002318 cardia Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 238000001723 curing Methods 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000010988 intraclass correlation coefficient Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 239000010937 tungsten Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 2
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 238000010146 3D printing Methods 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229910000677 High-carbon steel Inorganic materials 0.000 description 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910000861 Mg alloy Inorganic materials 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229960004733 albiglutide Drugs 0.000 description 1
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960000106 biosimilars Drugs 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229940095884 glucophage Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 238000005459 micromachining Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910001120 nichrome Inorganic materials 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000449 pharmaceutical disintegrant Substances 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 108700027806 rGLP-1 Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000021234 sugar-rich diet Nutrition 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 229950007151 taspoglutide Drugs 0.000 description 1
- 108010048573 taspoglutide Proteins 0.000 description 1
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 101150037438 tpm gene Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/0105—Steering means as part of the catheter or advancing means; Markers for positioning
- A61M25/0116—Steering means as part of the catheter or advancing means; Markers for positioning self-propelled, e.g. autonomous robots
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/007—Injectors for solid bodies, e.g. suppositories
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
- A61M2205/3344—Measuring or controlling pressure at the body treatment site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3368—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8218—Gas operated
- A61M2205/8231—Gas operated using electrochemical gas generating device for the driving gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8275—Mechanical
- A61M2205/8281—Mechanical spring operated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1042—Alimentary tract
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1042—Alimentary tract
- A61M2210/1053—Stomach
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/208—Blood composition characteristics pH-value
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/60—Muscle strain, i.e. measured on the user
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
本出願は、2019年3月20日に出願された米国仮特許出願第62/821,250号および2019年3月1日に出願された米国仮特許出願第62/812,867号に対する優先権およびその利益を主張し、両出願の完全な開示はともに参照によりあらゆる目的のために本明細書に組み込まれる。
本発明は、嚥下可能な薬物送達デバイスに関する。より具体的には、本発明は、治療剤を胃洞または胃壁の他の部分の中に送達するための嚥下可能な薬物送達デバイスに関する。
近年、様々な疾患の治療のための新しい薬物の開発が進んでいるが、タンパク質、抗体、ペプチド、および他の不安定な薬剤を含む多くの薬物は、経口投与できず、通常は、分解を避けるために静脈内または他の形態(例えば、筋肉内など)の非経口投与が必要であることから、用途が制限されている。胃の不快感および出血を含む合併症を伴う不良な経口耐性、胃内での薬物化合物の破壊/分解、および薬物の不良な、遅い、または一定しない吸収を含む、多くの理由のいずれかにより、薬物を経口で送達することができないことがある。
Claims (36)
- 固体投与治療剤調製物を患者に送達するための嚥下可能なデバイスであって、前記デバイスは、
カプセル壁を有する嚥下可能なカプセルと、
前記カプセルの内部に収容された固体投与治療剤調製物と、
前記固体投与治療剤調製物を前記カプセル壁を通って胃腸(GI)管の壁の中に前進させるように構成され、前記カプセルの内部にあり、可燃性推進剤および点火剤を含む、推進ドライバと、を備え、
前記点火剤は、前記カプセルの外部の条件に応答して前記可燃性推進剤を点火するように構成されている、嚥下可能なデバイス。 - 前記点火剤は、pH、圧力、および前記GI管の壁への近接性からなる群から選択される任意の1つ以上の外部条件の変化に応答して前記可燃性推進剤を点火するように構成されている、請求項1に記載のデバイス。
- 前記点火剤は、水分、温度、圧力、およびpHからなる群から選択される外部条件に応答して前記可燃性推進剤を点火するように構成されている、請求項1に記載のデバイス。
- 前記カプセル壁に埋め込まれ、前記点火剤に結合されたセンサをさらに備え、前記センサは、前記外部条件の値を感知し、前記外部条件の閾値に到達すると、前記点火剤に前記可燃性推進剤を点火させる、請求項1に記載のデバイス。
- 前記センサは電子式であり、前記感知された条件を表す電気信号を生じさせる、請求項4に記載のデバイス。
- 点火剤は、前記センサから前記感知された条件を表す前記信号を受信し、点火電流を生成し、前記点火電流を前記可燃性推進剤に送達するトリガ回路を備える、請求項5に記載のデバイス。
- 前記トリガ回路は、電池およびコンデンサを含み、前記電池は前記コンデンサを充電し、前記コンデンサは電荷を前記推進剤の中に放電する、請求項6に記載のデバイス。
- 前記トリガ回路は、前記推進剤に埋め込まれたワイヤフィラメントをさらに含み、前記ワイヤフィラメントは、前記電流が前記コンデンサから中を通って放電されるときに前記推進剤を点火するのに十分な熱を生じさせる、請求項7に記載のデバイス。
- 前記推進剤は、ニトロセルロースを含む、請求項8に記載のデバイス。
- 前記推進ドライバは、ピストンおよびシリンダを備え、前記可燃性推進剤は、前記ピストンの下の前記シリンダの底部にあり、前記固体投与治療剤調製物は、前記ピストンの上表面上にある、請求項1に記載のデバイス。
- 前記推進剤は、前記シリンダの前記底部に沿って形成されたニトロセルロースの層を含む、請求項10に記載のデバイス。
- 前記層は、0.1gm~0.5gmのニトロセルロースを含む、請求項1に記載のデバイス。
- 前記固体投与治療剤調製物は、テーパ状の、鋭利な、またはホーニングされた先端を有する細長い部材になるように、賦形剤または結合剤の少なくとも1つと圧縮された活性剤を含む、請求項1に記載のデバイス。
- 前記嚥下可能なカプセル壁は、円筒形シェルを備える、請求項1に記載のデバイス。
- 前記カプセル壁の少なくとも一部分が、患者の胃腸管内で分解性である、請求項1に記載のデバイス。
- 前記カプセル壁の少なくとも一部分が、患者の腸管内で分解性である、請求項15に記載のデバイス。
- 前記カプセル壁の前記少なくとも一部分は、約6.5以上のpHで分解する、請求項16に記載のデバイス。
- 前記固体投与治療剤調製物は、第1の固体投与治療剤調製物物および第2の固体投与治療剤調製物を含み、前記デバイスは、
前記第2の固体投与治療剤調製物を、前記第1の固体投与治療剤調製物とは異なる方向で駆動するように構成された第2の推進ドライバをさらに備える、請求項1に記載のデバイス。 - 前記推進ドライバおよび第2の推進ドライバは、前記第1の固体投与治療剤調製物および第2の固体投与治療剤調製物を少なくとも2つの正反対の方向で駆動するように構成されている、請求項18に記載のデバイス。
- 前記センサは、前記嚥下可能なカプセルの外部領域上に、前記外部条件の変化に応答して状態を変化させる機械的または流体センサ要素を含む、請求項1に記載のデバイス。
- 前記点火剤は、前記機械的または流体センサの状態の変化に応答し、機械的にエネルギーを生成して前記可燃性推進剤を点火する機械的または流体点火剤要素を含む、請求項20に記載のデバイス。
- 治療剤を患者の腸管の壁の中に送達するための方法であって、前記方法は、
前記治療剤調製物が内部に収容された嚥下可能なカプセルを提供することを含み、
前記患者は、前記嚥下可能なカプセルを摂取し、
前記カプセルは、内部に治療剤調製物を維持しながら、前記患者の胃腸(GI)管の最初の部分を通過し、
前記GI管内の外部条件に応答して前記カプセル内の可燃性推進剤が点火され、
前記点火された推進剤は、前記カプセルから前記GI管の壁の中に前記治療薬を注入する、方法。 - 前記カプセル内の前記可燃性推進剤は、pH、圧力、および前記GI管の壁への近接性からなる群から選択される外部条件の変化に応答して点火される、請求項22に記載の方法。
- 前記外部条件は、水分、温度、圧力、およびpHからなる群から選択される、請求項22に記載の方法。
- 前記可燃性推進剤をトリガして、前記治療剤を前記GI管の前記壁の中に注入するように、前記嚥下可能なカプセル上のセンサが結合されている、請求項22に記載の方法。
- 前記センサは、前記嚥下可能なカプセルの前記壁の中に組み込まれた電気トランスデューサを備える、請求項25に記載の方法。
- 前記電気センサは、前記治療剤を前記GI管の前記壁の中に注入するように、前記可燃性推進剤の点火を電気的にトリガする電気信号を生成する、請求項26に記載の方法。
- 前記センサは、前記嚥下可能なカプセルの前記壁の中に組み込まれた機械的または流体トランスデューサを備える、請求項25に記載の方法。
- 前記機械的または流体トランスデューサは、機械的または流体的に前記可燃性推進剤をトリガして、前記治療剤を前記GI管の前記壁の中に注入するように結合されている、請求項28に記載の方法。
- 前記可燃性推進剤を点火することは、点火電流を生成し、前記点火電流を前記可燃性推進剤に送達する回路をトリガすることを含む、請求項22に記載の方法。
- 前記回路をトリガすることは、コンデンサを電池で充電し、前記コンデンサからの電流を前記可燃性推進剤の中に放電することを含む、請求項30に記載の方法。
- 前記電流は、前記可燃性推進剤に埋め込まれたワイヤフィラメントの中に放電され、前記ワイヤフィラメントは、前記電流が前記コンデンサから中を通って放電されるときに前記推進剤を点火するのに十分な熱を生じさせる、請求項31に記載の方法。
- 前記可燃性推進剤は、ピストンの下のシリンダの底部にあり、前記固体投与治療剤は、前記ピストンの上表面上にある、請求項22に記載の方法。
- 前記治療剤は、前記カプセルから少なくとも2つの異なる方向で注入される、請求項22に記載の方法。
- 治療剤調製物を患者の胃の腔壁の中に送達するための嚥下可能なデバイスであって、前記デバイスは、
前記患者の胃腸管を通過するようにサイズ決定され、対向した側部および対向した端部を含む壁を有し、前記腔壁において、前記胃内で長手方向に配向するように構成された細長い形状を有する、カプセルと、
前記カプセルの内部にあり、治療剤を含み、組織貫通部材として成形されている、治療用調製物と、
前記カプセル壁の側壁部に配設され、前記カプセルの外部の条件を感知し、出力を生じさせるように構成されている、センサと、
前記組織貫通部材に動作可能に結合され、前記センサからの前記出力に応答し、推進剤の燃焼をトリガして、前記組織貫通部材を前記カプセルを通って前記腔壁の中に射出するように構成されている、射出器と、を備える、嚥下可能なデバイス。 - 前記カプセルは、前記カプセル壁の側部が前記洞の壁に隣接するように、前記胃の蠕動収縮中に前記胃内で長手方向に配向するように構成され、前記センサは、前記胃の蠕動収縮に対応する外部条件を感知することに応答して電気出力を生成するように構成され、前記デバイスは、
前記センサからの前記電気出力を分析し、前記外部条件の変化が検出されるとトリガ信号を生成するように構成された論理回路をさらに備える、請求項35に記載の嚥下可能なデバイス。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962812867P | 2019-03-01 | 2019-03-01 | |
US62/812,867 | 2019-03-01 | ||
US201962821250P | 2019-03-20 | 2019-03-20 | |
US62/821,250 | 2019-03-20 | ||
PCT/US2020/020544 WO2020180746A1 (en) | 2019-03-01 | 2020-02-28 | Propulsive drug delivery from a swallowable device into a patient's intestinal tract |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022523533A true JP2022523533A (ja) | 2022-04-25 |
JPWO2020180746A5 JPWO2020180746A5 (ja) | 2023-02-24 |
Family
ID=72236128
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021550223A Active JP7465886B2 (ja) | 2019-03-01 | 2020-02-28 | 治療剤を胃壁の中に送達するためのデバイス、システム、および方法 |
JP2021550224A Pending JP2022523533A (ja) | 2019-03-01 | 2020-02-28 | 嚥下可能なデバイスから患者の腸管の中への推進薬物送達 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021550223A Active JP7465886B2 (ja) | 2019-03-01 | 2020-02-28 | 治療剤を胃壁の中に送達するためのデバイス、システム、および方法 |
Country Status (10)
Country | Link |
---|---|
US (3) | US11565095B2 (ja) |
EP (2) | EP3930693A4 (ja) |
JP (2) | JP7465886B2 (ja) |
KR (2) | KR20220002275A (ja) |
CN (3) | CN116870341A (ja) |
AU (2) | AU2020233287A1 (ja) |
BR (2) | BR112021017289A2 (ja) |
CA (2) | CA3131779A1 (ja) |
MX (2) | MX2021010450A (ja) |
WO (2) | WO2020180746A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
WO2020180746A1 (en) | 2019-03-01 | 2020-09-10 | Rani Therapeutics, Llc | Propulsive drug delivery from a swallowable device into a patient's intestinal tract |
EP4302816A4 (en) * | 2021-03-05 | 2024-05-01 | Bitherapeutics Inc | ORAL MEDICINE DELIVERY DEVICE |
CN113576374B (zh) * | 2021-08-31 | 2022-08-30 | 武汉大学 | 一种板簧驱动的磁控施药胶囊机器人 |
CN113576373B (zh) * | 2021-08-31 | 2022-08-30 | 武汉大学 | 一种磁控微针穿刺施药胶囊 |
DK181266B1 (en) * | 2021-10-28 | 2023-06-14 | Biograil ApS | Drug delivery device with offset acutator mechanism |
WO2023148623A2 (en) * | 2022-02-01 | 2023-08-10 | Abhinav Goyal | Devices, insertion apparatus, and methods for administering samples |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6036047A (ja) * | 1983-07-13 | 1985-02-25 | スミスクライン・ベツクマン・コーポレイシヨン | 遅効性作用装置 |
JP2016529066A (ja) * | 2013-09-05 | 2016-09-23 | ヴェリリー ライフ サイエンシズ エルエルシー | 機能化粒子の送達 |
JP2016531623A (ja) * | 2013-09-26 | 2016-10-13 | メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ | 閾値放出を有する送達カプセル |
CN108686292A (zh) * | 2018-05-28 | 2018-10-23 | 重庆大学 | 一种释药胶囊 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI222370B (en) | 2001-12-14 | 2004-10-21 | Roche Diagnostics Gmbh | Needleless hypodermic injection device |
CA2514392A1 (en) | 2003-01-29 | 2004-08-12 | E-Pill Pharma Ltd. | Active drug delivery in the gastrointestinal tract |
US9700450B2 (en) * | 2003-07-28 | 2017-07-11 | Baronova, Inc. | Devices and methods for gastrointestinal stimulation |
US20080269664A1 (en) | 2005-01-18 | 2008-10-30 | Koninklijke Philips Electronics, N.V. | System and Method For Controlling Traversal of an Igested Capsule |
DE102005032369A1 (de) | 2005-07-08 | 2007-01-11 | Siemens Ag | Endoskopiekapsel |
US8591457B2 (en) | 2005-08-10 | 2013-11-26 | Alza Corporation | Method for making a needle-free jet injection drug delivery device |
US8597279B2 (en) | 2006-10-31 | 2013-12-03 | Medimetrics Personalized Drug Delivery, Inc. | Swallowable multi-nozzle dosing device for releasing medicines in the gastrointestinal tract |
EP2238885B1 (en) | 2008-06-04 | 2016-08-31 | Olympus Corporation | Capsule medical apparatus |
US20100286628A1 (en) * | 2009-05-07 | 2010-11-11 | Rainbow Medical Ltd | Gastric anchor |
US8356634B2 (en) | 2009-07-21 | 2013-01-22 | Piranha Hose Products | System for controlling elongation of a conduit within which flowable material is conveyed |
WO2011017335A1 (en) | 2009-08-03 | 2011-02-10 | Incube Labs, Llc | Swallowable capsule and method for stimulating incretin production within the intestinal tract |
AU2010336330B2 (en) | 2009-12-24 | 2016-04-28 | Rani Therapeutics, Llc | Swallowable drug delivery device and methods of drug delivery |
US8759284B2 (en) | 2009-12-24 | 2014-06-24 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8809271B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9149617B2 (en) | 2010-12-23 | 2015-10-06 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8846040B2 (en) | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8764733B2 (en) | 2010-12-23 | 2014-07-01 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
CA2949236C (en) | 2014-05-15 | 2023-06-13 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
US10689460B2 (en) | 2014-05-15 | 2020-06-23 | Incube Labs, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US10300259B2 (en) | 2014-10-22 | 2019-05-28 | Purdue Research Foundation | Smart capsule with GI-tract-location-specific payload release |
US10765361B2 (en) * | 2015-03-02 | 2020-09-08 | Verily Life Sciences Llc | Automated sequential injection and blood draw |
CA2983337A1 (en) | 2015-05-01 | 2016-11-10 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
CN109152796A (zh) | 2016-03-09 | 2019-01-04 | 因库博实验室有限责任公司 | 用于将活细胞递送至实体组织的方法和制品 |
US20170265598A1 (en) | 2016-03-15 | 2017-09-21 | Nike, Inc. | Method of making multi-colored objects |
US10286198B2 (en) | 2016-04-08 | 2019-05-14 | International Business Machines Corporation | Microchip medical substance delivery devices |
KR20200010332A (ko) | 2017-05-17 | 2020-01-30 | 메사추세츠 인스티튜트 오브 테크놀로지 | 자가-직립 시스템 및 관련 구성요소 및 방법 |
CA3082043A1 (en) | 2017-11-07 | 2019-05-16 | Rani Therapeutics, Llc | Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device |
WO2020180746A1 (en) | 2019-03-01 | 2020-09-10 | Rani Therapeutics, Llc | Propulsive drug delivery from a swallowable device into a patient's intestinal tract |
-
2020
- 2020-02-28 WO PCT/US2020/020544 patent/WO2020180746A1/en active Application Filing
- 2020-02-28 KR KR1020217030982A patent/KR20220002275A/ko unknown
- 2020-02-28 EP EP20765802.2A patent/EP3930693A4/en active Pending
- 2020-02-28 US US16/805,317 patent/US11565095B2/en active Active
- 2020-02-28 JP JP2021550223A patent/JP7465886B2/ja active Active
- 2020-02-28 CN CN202310832179.6A patent/CN116870341A/zh active Pending
- 2020-02-28 EP EP20766653.8A patent/EP3930688A4/en active Pending
- 2020-02-28 BR BR112021017289A patent/BR112021017289A2/pt unknown
- 2020-02-28 CN CN202080028728.9A patent/CN113692275B/zh active Active
- 2020-02-28 WO PCT/US2020/020540 patent/WO2020180745A1/en active Application Filing
- 2020-02-28 AU AU2020233287A patent/AU2020233287A1/en active Pending
- 2020-02-28 KR KR1020217030993A patent/KR20220002876A/ko unknown
- 2020-02-28 AU AU2020232610A patent/AU2020232610A1/en active Pending
- 2020-02-28 BR BR112021017288A patent/BR112021017288A2/pt unknown
- 2020-02-28 CN CN202080028786.1A patent/CN113692274A/zh active Pending
- 2020-02-28 US US16/805,583 patent/US11833319B2/en active Active
- 2020-02-28 CA CA3131779A patent/CA3131779A1/en active Pending
- 2020-02-28 CA CA3131781A patent/CA3131781A1/en active Pending
- 2020-02-28 MX MX2021010450A patent/MX2021010450A/es unknown
- 2020-02-28 MX MX2021010442A patent/MX2021010442A/es unknown
- 2020-02-28 JP JP2021550224A patent/JP2022523533A/ja active Pending
-
2022
- 2022-12-27 US US18/089,478 patent/US20230137442A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6036047A (ja) * | 1983-07-13 | 1985-02-25 | スミスクライン・ベツクマン・コーポレイシヨン | 遅効性作用装置 |
JP2016529066A (ja) * | 2013-09-05 | 2016-09-23 | ヴェリリー ライフ サイエンシズ エルエルシー | 機能化粒子の送達 |
JP2016531623A (ja) * | 2013-09-26 | 2016-10-13 | メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ | 閾値放出を有する送達カプセル |
CN108686292A (zh) * | 2018-05-28 | 2018-10-23 | 重庆大学 | 一种释药胶囊 |
Also Published As
Publication number | Publication date |
---|---|
US20200276426A1 (en) | 2020-09-03 |
AU2020233287A1 (en) | 2021-09-23 |
WO2020180746A1 (en) | 2020-09-10 |
CN113692275B (zh) | 2023-07-25 |
KR20220002876A (ko) | 2022-01-07 |
EP3930693A4 (en) | 2023-01-11 |
EP3930688A4 (en) | 2022-11-30 |
WO2020180745A1 (en) | 2020-09-10 |
BR112021017289A2 (pt) | 2021-12-28 |
CN113692275A (zh) | 2021-11-23 |
JP7465886B2 (ja) | 2024-04-11 |
EP3930688A1 (en) | 2022-01-05 |
CA3131781A1 (en) | 2020-09-10 |
US11833319B2 (en) | 2023-12-05 |
AU2020232610A1 (en) | 2021-09-23 |
CN113692274A (zh) | 2021-11-23 |
JP2022523532A (ja) | 2022-04-25 |
KR20220002275A (ko) | 2022-01-06 |
MX2021010450A (es) | 2021-12-10 |
BR112021017288A2 (pt) | 2021-12-28 |
US20230137442A1 (en) | 2023-05-04 |
CN116870341A (zh) | 2023-10-13 |
MX2021010442A (es) | 2021-12-10 |
US20200276425A1 (en) | 2020-09-03 |
US11565095B2 (en) | 2023-01-31 |
EP3930693A1 (en) | 2022-01-05 |
CA3131779A1 (en) | 2020-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022523533A (ja) | 嚥下可能なデバイスから患者の腸管の中への推進薬物送達 | |
US11338118B2 (en) | Swallowable drug delivery device and methods of drug delivery | |
JP6745866B2 (ja) | 嚥下可能な薬物送達デバイスを用いる腸管の内腔へ送達するための治療剤製剤 | |
US20240139479A1 (en) | Propulsive drug delivery from a swallowable device into a patient's intestinal tract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230215 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230215 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231024 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231025 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240116 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240326 |